Progress toward in vivo use of siRNAs-II

N/ACitations
Citations of this article
311Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

RNA interference (RNAi) has been extensively employed for in vivo research since its use was first demonstrated in mammalian cells 10 years ago. Design rules have improved, and it is now routinely possible to obtain reagents that suppress expression of any gene desired. At the same time, increased understanding of the molecular basis of unwanted side effects has led to the development of chemical modification strategies that mitigate these concerns. Delivery remains the single greatest hurdle to widespread adoption of in vivo RNAi methods. However, exciting advances have been made and new delivery systems under development may help to overcome these barriers. This review discusses advances in RNAi biochemistry and biology that impact in vivo use and provides an overview of select publications that demonstrate interesting applications of these principles. Emphasis is placed on work with synthetic, small interfering RNAs (siRNAs) published since the first installment of this review which appeared in 2006. © The American Society of Gene & Cell Therapy.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Rettig, G. R., & Behlke, M. A. (2012). Progress toward in vivo use of siRNAs-II. Molecular Therapy. Nature Publishing Group. https://doi.org/10.1038/mt.2011.263

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 140

66%

Researcher 56

26%

Professor / Associate Prof. 10

5%

Lecturer / Post doc 7

3%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 87

49%

Biochemistry, Genetics and Molecular Bi... 44

25%

Medicine and Dentistry 31

17%

Chemistry 17

9%

Article Metrics

Tooltip
Mentions
References: 1

Save time finding and organizing research with Mendeley

Sign up for free